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Abstract 
Nowadays, the presence of HBV DNA in the absence of HBsAg; occult hepatitis B infection; (OBI), is a known 
clinical entity along with the rapid influx of research being conducted on  its clinical relevance. Biologists and 
clinicians alike have a recent-standing interest in this regards. OBI has been described in several clinical settings. 
However, the data on its prevalence among immunized and non-immunized healthy general population, in particular, 
among health care workers (HCWs) is ambigous. This review attemps to explore the significance of OBI in 
vaccinated groups as a special subject. The prevalence of OBI among general population, vaccinated 
children/general population and health care workers were: 157 (5.2%), 222 (6.7%) and 33 (1.8%), respectively. The 
prevalence of anti-HBc among OBI-positive subjects were: 64 (40.7%), 133 (82.7%) and 27 (81.8%), respectively. 
OBI is partly prevalent in general population and in vaccinated individuals, especially in those who born to HBsAg 
positive mothers. HBV serological surveys are not enough adequate and sensitive to rule out the presence of HBV 
DNA. For high-risk groups (subjects born to HBsAg mothers, health care workers, isolated anti-HBc, etc) sensitive 
molecular tests based on real time PCR should be applied for a proper diagnosis. 
Keywords: occult hepatitis B infection, general population, Health care workers, HBV vaccine 
 
*Corresponding Author: Seyed Mohammad Jazayeri. Tel: (+98) 21-8899 2660; Email: jazayerism@tums.ac.ir 
 
Please cite this article as: Alavian SM, Jazayeri SM. Occult Hepatitis B infection (OBI) in vaccinated groups, a metanalysis. Arch Med 




The clinical importance of occult hepatitis B 
(OBI) has been a matter of debate for the past few 
years, given its clinical and epidemiological 
implications.  Although OBI has been described in 
various clinical settings (Fig 1), the clinical 
significance and associated risks of occult HBV 
infection may differ in various patient populations.  
Two studies have explored the distribution of 
hepatitis B virus (HBV) in the livers of patients with 
OBI; these studies showed that the percentage of 
hepatocytes containing HBV DNA and the level of 
intrahepatic HBV DNA were statistically lower in 
OBI-infected patients than in chronic HBsAg carriers 
[1, 2].  However, the molecular mechanism, dynamic 
fluctuation, and health risk of occult hepatitis cannot 
be accurately delineated through cross-sectional, case 
series, or case-control studies.  The best approach is a 
population-based and  long-term follow-up study on a 
randomly selected cohort with repeated measurements 
of HBV infection markers including serology and 
HBV DNA.  
OBI has been implicated in the transmission of 
HBV via transfusion of blood and realted products 
[3]. Other studies have also documented the 
transmission and development of OBI via organ 
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transplantation, from mother to child, and from 
humans to chimpanzees [4-8]. Finally, occult HBV 
can be transmitted with few or no signs of ongoing 
viral replication [5, 9-12].  
A major question about occult HBV is whether 
such small amounts of HBV DNA are associated with 
progressive liver damage in the individual.  In the vast 
majority of patients with OBI infection, however, a 
low threshold level of HBV DNA (<1,000 copies/mL) 
may not be sufficient to cause progressive liver 
disease in immunocompetent chronic HCV patients, 
as demonstrated in previous studies [13].   
The literature has discussed OBI in diverse 
clinical settings (Fig 1).  However, no study has been 
focused on the reported prevalence of OBI among 
health care workers and immunized as well as 
nonimmunized general population yet. The aim of this 
review was to explore the details of diagnosed OBI in 
these special groups.  
Evidence Acquisition 
A comprehensive electronic literature search 
using Pubmed was carried out by following medical 
subject headings (MeSH) and combination of free text 
words: occult hepatitis B infection along with 
keywords: general population, health care workers 
and vaccinated subjects. The inclusion of health care 
workers in this category was due to the fact that this 
group of people is a part of general population (and 
not patients) who involved in health care settings. 
Also, recent published data globally indicated that a 
majority of HCWs have been received at least a  
single dose of vaccine prior or after they engagement 
 
Figure 1. A schematic phylogenetic tree showing the association of occult hepatitis B in different clinical settings.  The length of each branch 
symbolizes the weight of published papers for those settings. 
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in health care settings. All published data since 2001 
(the explanation of OBI) until April 2014 have been 
included in the study. The inclusion criteria for the 
study were: all studies showing  the presence of HBV 
DNA in the absence of HBsAg regardless of 
antibodies to core and/or surface proteins. 
General population  
 The OBI prevalence for healthy individuals 
who were tested negative for HBsAg and positive or 
negative for either anti-HBs or anti-HBc or both 
ranges from 0.7% to 18% (Table 1), whereas the 
prevalence of previous HBV exposure in these 
populations has been found to range between 6.1 and 
51% [14-18]. The prevalence of anti-HBc positivity in 
OBI cases in general population-studied was between 
22% and 66.6% as a whole (Table 1). 
Minuk et al investigated the prevalence of OBI 
in two publications from Canada. In the first study, 
487 samples were collected from Eskimo community. 
They classified into two groups: 80 and 407 for HBV 
serologic markers positive and negative, respectively. 
The prevalence of OBI was 18% and 8%, 
respectively. Moreover, 86% and 52% were contained 
surface protein mutations, respectively[17]. In the 
second study, 706  HBsAg-negative sera were 
collected from three Northern Canadian communities  
with known HBsAg prevalence of 11–12%. The rate 
of OBI was 1.3% [19]. Both of these studies have  
Table 1: Details of occult hepatitis B infection prevalence among general population.  
Note *: prevalence of anti-HBc in OBI-positive cases. 
 
No Author Country Number of  
Samples 








1 Fang/2009 [14] China 359 38 (10.6) 14 (33.3) - 
2 Kim/2007 [15] Korea 195 31 (16) 16 (51.6) - 
3 Minuk/2012 [19] Canada 706 9 (1.3) 2 (22) - 





II: 14 (18) 
14 (29.7) I:12 (86%) 
II:17 (52%) 
contained  surface 
protein mutations 
5 Song/2009 [50] Korea 1047 7 (0.7) 2 (28.5) Three cases contained 
mutation within and 
outside of “a” 
determinant. 
6 Hwang/2010 [20] USA 118 9 (7.6) 6 (66.6) - 
7 Raimondo/2008 [18] Italy 98 16 (16.3) 10 (62.5) - 
 Total  3010 157 (5.2) 64 (40.7) - 
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Table 2: Reported prevalence of OBI obtained from blood specimens collected from vaccinated individuals. Note *: 
prevalence of anti-HBc in OBI-positive cases.  






Study Subjects Mutational study 
results 
1 Mu/2009 [24] Taiwan 46 5 (10.9) None Normal children C139S vaccine 
escape mutant  and 
variation and 
deletion were found 
in pre-S1.  
2 Meschi/2010 [22] Tanzania 282 1(0.35) 1 (100) 
 
Normal children - 
3 Utsumi/2010 [23] Indonesia 229 5 (2.1) 4 (80) Normal children All contained 
mutations in S and 
or Pre-S proteins. 
4 Xu/2010 [25] China 2218 81 (2.7) 81 (100) Gen population 





5 Shahmoradi/2012 [27] Iran 75 21 (28)  5 (23.8) Children born to HBsAg 
positive mothers 
13 infected children 
(62%) had at least 
one mutation. 10 
had G145R 
mutations. 
6 Chakvetadze/2011 [26] France 
(Africans) 
100 2 (2) 1 (50) Children born to HBsAg  
positive  mothers 
- 
7 Pande/2013 [28] India 213 89 (42) NI Children born to HBsAg  
positive  mothers 
- 
8 Pereira/2006 [30] Brazil I: 100 
II: 50 
I: 6 (6%) 
II: 12 (24%) 
18 (100) I:Blood donors 
II: HCV positive 
- 
 Total  3313 222 (6.7) 133 (82.7)   
NI, not identified. 
been carried out in Northern region of Canada, 
especially amongst either Eskimo or Northwest 
Territories, known for high endemicity for HBV 
infection. 
Raimondo et al found a massive prevalence 
(16.3%) of OBI in 98 patients who admitted to the 
hospital for abdominal surgery (non-liver disease 
complaints). In details, 10 out of these 16 patients 
were anti-HBc positive. Despite authors claimed that 
almost  6.1 of the Italian general population might be 
carriers of occult HBV infection, however, the 
relative small number of cases in Raimondo’s study 
prevents to draw a net conclusion and it must surely 
be simplistic to extend this finding to general 
population. 
Hwang et al. found a prevalence of 7.6% of 
OBI amongst 118 Asian-American general population 
from the USA [20]. The prevalence of positive HBV  
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Table 3: Reported prevalence of OBI from health care workers. 
No Author Country No Samples Number (%) of OBI 
positive cases 





Iran 122 4 (3.3%) 0 (0) Vaccinated Non-Responders 
2 Chiarakul 
/2011(35) 
Thailand 36 4 (11%) 4 (100) Non- Responders 
3 Slusarczyk 
/2012(37) 
Poland 961 6 (4%) 4 (100) vaccinated 
4 Shim/2011(36) Korea 334 0% 0 Responders /non- Responders 
5 Sukriti/2008(3
4) 
India 120 6 (5%) 6 (100) Responders 
6 Yen/2005(33) Taiwan 250 13 (6.4%)** 13 (100) Non Responders 
 Total  1823 33 (1.8) 27 (81.8)  
Note *: prevalence of anti-HBc in OBI-positive cases. **: 16/23 samples were available for HBV DNA testing 
markers; as overt HBV infection, was 10.2% among 
patients-studied. There are numerous reports coming  
up from the USA regarding a high prevalence of HBV 
serologic markers in Asian-American who already 
migrated to the USA. 
An interesting study from Korea, apreviously-
known region with  high prevalence for HBsAg 
carriers reported that  the rate of OBI was 0.7% (7 out 
of 1047) (Table 1). The mean age of participants was 
not mentioned in this paper; however, 1000 out of 
1047 population were ≥30 years old, born long before 
the commencement of HBV immunization in Korea 
in 1983. Sequencing of HBV S gene in three cases 
revealed one wild-type and two mutant strains. 
Similarly, An et al. from Korea reported a low 
prevalence of OBI between vaccinated children 
(0.9%). On the other hand, previous studies from the 
same area reported prevalence of 11.4 [21] to 16% 
[15] using more sensitive techniques.  The age 
differences could be the reason for these wide gaps 
between different prevalence of OBI.Specifically,  it 
can be related to the vaccine coverage rate started in 
1983 in Korea which lowered the endimicity of HBV 
infection as a whole. Collectively, among 3010 
population-studied, 157 (5.2%) were positive for OBI 
of whom 64 (40.7%) were anti-HBc positive (Figure 
2). 
HBV-vaccinated Individuals  
Of nine  studies undertaken for OBI in 
vaccinated individual, three  were carried out on 
normal children who received the vaccine according 
to standard protocols. The prevalence of OBI among 
these populations was ranged between 0.35% and 
10.9% [22-24] (Table 2). Another study carried out on 
vaccinated general population with a mean age of 19-
21 years who were positive for both anti-HBs and 
anti-HBc, showed 2.7% OBI frequency [25].   124.16 
anti-HBc and anti-HBs positive cases were born from 
HBsAg positive mothers. This investigation was 
included the adults who had been vaccinated during 
1980s-1990s. Only 9.8% showed mutations at the “a” 
epitope and three of them were G145A. The other 
class of studies was undertaken on high risk 
communities who were born to HBsAg positive 
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mothers. The frequency of OBI was between 2% and 
42% [26-28]. In a majority of these studies, vaccine 
failure was observed due to occult HBV infection 
despite the presence of adequate levels of anti-HBs 
(Table 2). In a study from Taiwan, of 46 vaccinated 
children, 5 (10.9%) were found to have OBI [24].  
Another study from Iran, indicated the presence of 
HBV DNA in 21 of 75 (28%) children borrn to 
HBsAg-positive mothers who had already been 
immunized with an HBIG and vaccine prophylaxis 
regimen [29].  All OBI-infected children were anti-
HBs positive with protection titers (>10IU/mL). In 
both studies, multiple-point mutations (including a-
determinant vaccine escape mutants) and deletions 
were found in different parts of the HBV genome in 
OBI-positive individuals.   In a similar study from 
India, Pande et al. found that 142 out of 222 (64%) of 
babies born to HBsAg positive mothers acquired OBI 
at the end of primary end point of the study (week 
18
th
 after birth). At month 24, 89 (42%) were OBI-
positive. Authors were found that the anti-HBs status 
at 18 weeks of babies who acquired OBI was an 
important indicator for subsequent outcomes. Also, 
85% of babies had adequate anti-HBs titers at 18 
weeks, while 15% had inadequate anti-HBs titres. 
From the former group, 36% lost their infection, 
while from the latter group, only 15% lost their 
infection (P < 0.05). These two latter studies which 
showed a massive prevalence of OBI (28% and 42%, 
respectively) among children born to HBsAg positive 
mothers despite immunoprophylaxis with vaccine and 
HBIG, underscore the importance of OBI as a clinical 
entity in these high-risk group individuals. 
In a study by Pereira et al. 100 blood donors 
and 50 anti-HCV positive individuals  who were 
positive for anti-HBc only found to be positive for 
OBI; 6 (6%) and 12 (24%), respectively. 22 HCV-
positive patients and all blood donors received three 
doses of HBV vaccine. All (100%) and 12.9 (75%) of 
OBI-positive became HBV DNA negative after few 
months post-diagnosis, respectively [30].   
Altogether, of total 3313 subjects-studied, 222 
(6.7%) were OBI-positive of whom 133 (60%) were 
positive for anti-HBc (Figure 2). 
Health Care workers 
Health care workers are at the front line for 
acquisition of blood-borne viruses. Compared to 
general population, the risk of acquiring HBV for 
HCW is estimated to be 16 to 30% [31, 32]. 
Regarding the prevalence of OBI in this special 
group, as it shown in Table 3, these values ranged 
between 3.3 and 11%. 
In an unpublished data from Iran, our group 
found a prevalence of 3.3% of HCW who harbored 
OBI. All subjects in this study were chosen from 
individuals who did not respond to 3 standard doses 
 
Figure 1. A diagram showing the percentages of positive HBV occult infection and the frequency of positive anti-HBc between OBI positive cases in the 
selected studies. The light green columns show the number of samples, blue columns indicate the number of OBI-positive cases and red columns show 
the number of positive cases between OBI patients. 
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of HBV vaccine. None of index patients were positive 
for anti-HBc. In molecular analysis, no subjects were 
contained mutations in the whole surface proteins. 
In another study, 250 health care workers who 
completed their hepatitis B vaccination, were divided 
into 2 groups: anti-HBc positive (n=78) and anti-HBc 
negative (n=172). Both groups were vaccinated by 
three doses of HBV vaccine. 23 (29.5%) and 11 
(6.4%) were non-responders in both groups, 
respectively.  Among 23 non-responders in anti-HBc 
positive subjects, blood samples were obtained from 
16 subjects.  HBV DNA was positive in all these 16 
subjects. 
23 were nonresponders, and of 16 available 
samples, 13 had OBI (Table 3) [33].   
In a study from India [34], a vast number of 
HCWs was screened for HBV markers.  Of the 2141 
HCWs who were negative for HBsAg,  anti-HBc 
testing was done in 700 subjects. A total of 200 
(24.7%) were found to be positive, showing evidence 
of past exposure to hepatitis B infection. Of these 200 
subjects, 120 were  tested for OBI. 6 (5%) were OBI 
positive with adequate levels of anti-HBs.   Among 
the 115 subjects who had prior exposure, but not 
reported to have occult HBV infection, 87% were 
anti-HBs-positive even though they did not receive 
any vaccination. These results underscore the fact that 
a fair proportion of HCWs might be infected by 
cryptic feature of HBV without any acknowledge that 
would never been explored by current molecular 
techniques.  
In a group of 548 Thai HCWs, Chiarakul et al, 
found a frequency of 11% (n=4) OBI among 36 HCW 
with isolated anti-HBc. None of persons were 
responded to a single dose of booster vaccine[35]. 
In a study from Korea, a known endemic area 
for HBV, a group of 334 HCWs were divided into 
two groups: isolated anti-HBc (n=40) and 294 who 
were negative for all HBV markers. After 3 doses of 
vaccine, 10 (25%) and 98 (33.3%) were showed an 
amnestic response to vaccine and the rest were failed 
to response. Interestingly, none groups were positive 
for OBI [36].  This finding came as something of a 
surprise, as the total isolated anti-HBc subjects were 
only 2.2% (40 out of 1757). 
In Poland, of 961 HCWs, 151 (15.7%) were 
positive for anti-HBc, of whom 98.7% (149) were 
positive for anti-HBs as well. OBI was detected in 6 
(4%) of cases [37].  
None of such studies on HCWs contained 
mutational analysis. However, in our unpublished 
study, we did not find any mutations in surface 
proteins of subjects. Interestingly,  the prevalence for 
OBI and anti-HBc positivity in OBI cases were 1.8% 
and (81.8%), respectively (Figure 2).  
 
Discussion 
A growing body of literatures have shown that 
occult HBV infection could be expected to occur any 
clinical settings (Fig 1). Adequate molecular 
epidemiology databases of this clinical entity are 
important for infection prevention and control 
managements and treatment programs. 
The selected, available papers on the 
prevalence of OBI in general population suffer from 
bias on sample collections according to age, HBV 
hyperendemicity, methodology used and vaccine 
coverage. Almost all the data have come from areas 
with high HBV endemicity (Eskimos, south-east 
Asian countries, Italy, etc). More cross -sectional 
studies from low to intermediate HBV endemic 
regions need to be carried out to explore the exact 
prevalence of OBI in general population. Worldwide 
coverage rate of 80% for HBV vaccine is another 
issue which should be taken into account. This factor 
would influence the results of such investigations 
dramatically. In addition, other limitation for above 
mentioned studies is the lack of clarification for the 
status of HBV immunization in their investigations, 
despite anti-HBs positivity in some of cases, adding 
more confusion about either past history of HBV 
infection or outstanding of antibody after 
immunization. 
The occurrence of OBI in immunized 
individuals with adequate, protective levels of anti-
HBs is a matter of debates. For high risk subjects, 
previous contact with HBV (vertical or horizontal) 
might prevent the effects of vaccine/HBIg for proper 
neutralization of HBsAg. To add to the confusion, the 
tiny amount of HBV DNA in the presence of anti-
HBs may not be quiet efficient for HBV replication. 
Pande et al., found that 36%  of OBI-positive high-
risk infants lost their infection after a period of six 
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month post-diagnosis. All of these patients had 
protective levels of anti-HBs at the time of diagnosis. 
If it is the case, therefore, testing of sequential 
samples in certain intervals would explore the real 
situation of OBI in cohort, longitudinal studies which 
could reveal the outcomes of this complicated clinical 
situation. 
There are scarce data on the prevalence of OBI 
in HCWs worldwide. However, the presented data in 
this section underscores the importance of this clinical 
entity in this high risk group. In a majority of the 
following studies, the molecular tests were carried out 
on anti-HBc positive samples (regardless of being 
either isolated or being also positive for anti-HBs). 
However, our unpublished results are the only data on 
screening of HBsAg negative HCWs regardless of 
other HBV serologic markers results. 
What is the significance of OBI in these 
individuals? Several epidemiological and molecular 
studies which are  supported by animal models 
encouraged the hypothesis that OBI retains the same 
pro-oncogenic features and accelerates the 
progression of liver disease and the development of 
cirrhosis [38, 39]. Moreover, despite the strong 
association between HCC and seropositivity of 
HBsAg, almost all clinical and epidemiological 
studies have observed HBsAg-sero negative patients 
affected with HCC and liver cirrhosis [10, 18, 40, 41].   
The other issue includes the reactivation of 
hepatitis due to OBI. HBV is now a well-recognized 
complication in patients with chronic HBV infection 
receiving cytotoxic, corticosteroid, or 
immunosuppressive therapy.  In these cases, 
reactivation of the virus may occasionally be present, 
leading to severe or even fulminant hepatic failure 
sometimes indistinguishable from de novo acute 
infection [42-44]. In this respect, HBV reactivation  
has been observed in advanced immune deficiency in 
patients with hematological-malignancy disorders, at 
a prevalence of 3.3% to 24% [45-48]; and subjects 
who were HBsAg negative prior to chemotherapy 
(alkylators, antimetabolites, antitumor antibiotics, 
corticosteroids, etc. ) who underwent treatment  and 
transplantation especially those treated with rituximab 
(anti-CD20), alemtuzumab (anti-CD52), and 
infliximab (anti-TNF) [47-49]. 
A vast majority of publication highlighted the 
importance of anti-HBc, either isolated or in the 
presence of anti-HBs, as a useful serologic marker for 
the probability of OBI diagnosis. Naively speaking, 
one would expect that anti-HBc testing can be helpful 
for identification of cases for HBV DNA testing in 
terms of patients’ selection and cost benefit issues. 
However, it is not the case. Rather, as described 
earlier [39], results from this study confirmed that a 
fair proportion of  anti-HBc negative cases were OBI-
positive. Therefore, relying on this serologic marker 
would underestimate the real prevalence of OBI. 
Concluding Remarks 
This metanalysis clearly showed that OBI 
cannot be ignored even in immunized individuals. In 
the process of moving from evidence to 
recommendations, the following were considered. 
First, HBV serological surveys are not enough and 
sensitive to rule out the presence of HBV DNA. For 
high-risk groups (subjects born to HBsAg mothers, 
health care workers, isolated anti-HBc, etc) sensitive 
molecular tests based on real time PCR should be 
applied for a proper diagnosis. Secondary, due to 
intermittent HBV replication and hopefully clearance 
of HBV, those who have been diagnosed with OBI, 
should be monitored periodically by molecular tests 
to verify the persistence of OBI (especially in those 
who showed protective levels of anti-HBs). 
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